phosphorylcholine has been researched along with Benign Neoplasms, Brain in 42 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 7.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 7.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 7.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| "ErPC (40 mg/kg) was given to C6 glioma-bearing rats either as a single intracarotid bolus injection in the presence or absence of 1- O-pentylglycerol (300 m M) or as an intracarotid infusion in conjunction with bradykinin." | 7.71 | Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M, 2002) |
| "In the present study we investigate the effect of exogenous sphingosine, sphingosine 1-phosphate and sphingosylphosphorylcholine on phospholipase D (PLD) activity in glioma C6 cells." | 7.70 | Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells. ( Barańska, J; Bobeszko, M; Dygas, A; Sidorko, M, 1999) |
| "The effect of sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate on L-[U-14C]serine incorporation into phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine was investigated in intact glioma C6 cells." | 7.70 | Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. ( Barańska, J; Wójcik, M, 1999) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 6.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 6.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Primary glioblastoma multiforme is the most malignant form of astrocytic tumor with an average survival of approximately 12-14 months." | 5.39 | The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. ( Fu, LS; Guo, J; Qin, LS; Sun, G; Xu, J; Yu, ZQ; Zhang, SM; Zhu, J, 2013) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 5.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Erucylphosphocholine (ErPC) is a promising antineoplastic drug for the treatment of malignant brain tumors." | 5.32 | MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M; Otten, K, 2004) |
| "Previous ex vivo spectroscopic data from tissue samples revealed differences in phospholipid metabolites between isocitrate dehydrogenase mutated (IDHmut) and IDH wildtype (IDHwt) gliomas." | 3.91 | In vivo Metabolic Profiles as Determined by ( Bähr, O; Franz, K; Hattingen, E; Pilatus, U; Steinbach, J; Wenger, KJ, 2019) |
| "A series of polymer-drug conjugates based on 2-methacryloyloxyethyl phosphorylcholine (MPC) was prepared with the glioblastoma drug temozolomide (TMZ) as pendent groups." | 3.88 | Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma. ( Emrick, T; Saha, B; Skinner, M; Ward, SM, 2018) |
| "Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor." | 3.85 | In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. ( Agliano, A; Al-Saffar, NMS; Balarajah, G; Clarke, PA; Jackson, LE; Jones, C; Leach, MO; Marshall, LV; Pearson, ADJ; Sidhu, J; Workman, P, 2017) |
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 3.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| "ErPC (40 mg/kg) was given to C6 glioma-bearing rats either as a single intracarotid bolus injection in the presence or absence of 1- O-pentylglycerol (300 m M) or as an intracarotid infusion in conjunction with bradykinin." | 3.71 | Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M, 2002) |
| "The authors sought to compare 1H magnetic resonance spectroscopy (MRS) spectra from extracts of low-grade and high-grade gliomas, especially with respect to the signals of choline-containing compounds." | 3.70 | Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. ( Berry, I; Breil, S; Delisle, MB; Gilard, V; Malet-Martino, M; Manelfe, C; Ranjeva, JP; Sabatier, J; Terral, C; Tremoulet, M, 1999) |
| "In the present study we investigate the effect of exogenous sphingosine, sphingosine 1-phosphate and sphingosylphosphorylcholine on phospholipase D (PLD) activity in glioma C6 cells." | 3.70 | Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells. ( Barańska, J; Bobeszko, M; Dygas, A; Sidorko, M, 1999) |
| "The effect of sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate on L-[U-14C]serine incorporation into phosphatidylserine and phosphatidylserine-derived phosphatidylethanolamine was investigated in intact glioma C6 cells." | 3.70 | Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells. ( Barańska, J; Wójcik, M, 1999) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 2.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 2.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Many types of cancer, for example glioblastoma, show resistance against current anti-cancer treatments." | 2.50 | Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment. ( Gavish, M; Kugler, W; Veenman, L, 2014) |
| "Glioblastoma is a highly malignant brain tumor that relentlessly defies therapy." | 2.47 | Genetics of glioblastoma: a window into its imaging and histopathologic variability. ( Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA, 2011) |
| "Glycine was detected in 24% of all studies, though with a wide range of signal amplitude and extent of the spatial distributions." | 1.40 | Mapping of glycine distributions in gliomas. ( Behari, S; Gupta, RK; Hussain, N; Maudsley, AA; Parra, NA; Roy, B; Sheriff, S; Stoyanova, R, 2014) |
| "Primary glioblastoma multiforme is the most malignant form of astrocytic tumor with an average survival of approximately 12-14 months." | 1.39 | The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells. ( Fu, LS; Guo, J; Qin, LS; Sun, G; Xu, J; Yu, ZQ; Zhang, SM; Zhu, J, 2013) |
| "Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell lines, and is currently being tested in several phase II trials for treatment of major human cancers." | 1.33 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. ( Holland, EC; Momota, H; Nerio, E, 2005) |
| "Erucylphosphocholine (ErPC) is a promising antineoplastic drug for the treatment of malignant brain tumors." | 1.32 | MAP kinase pathways involved in glioblastoma response to erucylphosphocholine. ( Eibl, H; Erdlenbruch, B; Jendrossek, V; Kugler, W; Lakomek, M; Otten, K, 2004) |
| "Eighty-five brain metastases in 81 patients were investigated before treatment and 16-18h thereafter." | 1.32 | Early metabolic changes in metastatic brain tumors after Gamma Knife radiosurgery: 1H-MRS study. ( Abe, K; Chernov, MF; Hayashi, M; Hori, T; Izawa, M; Kubo, O; Ono, Y; Usukura, M, 2004) |
| "Erucylphosphocholine (ErPC) is a promising candidate for the treatment of human brain tumors." | 1.31 | Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. ( Eibl, H; Erdlenbruch, B; Hammersen, K; Jendrossek, V; Krügener, R; Kugler, W; Lakomek, M, 2002) |
| "Choline was elevated in the cellular portion of both tumors but decreased in the necrotic or cystic portions." | 1.29 | Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. ( Booth, RA; Buchthal, SD; Chang, L; Cornford, M; Ernst, TM; Jenden, D; McBride, D; Miller, BL, 1995) |
| "The pH of brain tumors (7." | 1.28 | P-31 MR spectroscopy of normal human brain and brain tumors. ( Hubesch, B; Matson, GB; Meyerhoff, DJ; Roth, K; Sappey-Marinier, D; Weiner, MW, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (19.05) | 18.2507 |
| 2000's | 13 (30.95) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 4 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, H | 1 |
| Chao, Y | 1 |
| Zhao, H | 1 |
| Zhou, X | 1 |
| Zhang, F | 1 |
| Zhang, Z | 1 |
| Li, Z | 2 |
| Pan, J | 1 |
| Wang, J | 1 |
| Chen, Q | 1 |
| Liu, Z | 1 |
| Sandbhor, P | 1 |
| Goda, JS | 1 |
| Mohanty, B | 1 |
| Chaudhari, P | 1 |
| Dutt, S | 1 |
| Banerjee, R | 2 |
| Kaley, TJ | 2 |
| Panageas, KS | 2 |
| Pentsova, EI | 1 |
| Mellinghoff, IK | 2 |
| Nolan, C | 2 |
| Gavrilovic, I | 1 |
| DeAngelis, LM | 2 |
| Abrey, LE | 2 |
| Holland, EC | 3 |
| Omuro, A | 1 |
| Lacouture, ME | 1 |
| Ludwig, E | 1 |
| Lassman, AB | 2 |
| Ban, J | 1 |
| Li, S | 1 |
| Zhan, Q | 1 |
| Li, X | 1 |
| Xing, H | 1 |
| Chen, N | 1 |
| Long, L | 2 |
| Hou, X | 1 |
| Zhao, J | 1 |
| Yuan, X | 2 |
| Wang, N | 1 |
| Sun, P | 1 |
| Lv, M | 1 |
| Tong, G | 1 |
| Jin, X | 1 |
| Zhu, X | 1 |
| Al-Saffar, NMS | 1 |
| Agliano, A | 1 |
| Marshall, LV | 1 |
| Jackson, LE | 1 |
| Balarajah, G | 1 |
| Sidhu, J | 1 |
| Clarke, PA | 1 |
| Jones, C | 1 |
| Workman, P | 1 |
| Pearson, ADJ | 1 |
| Leach, MO | 1 |
| Wenger, KJ | 1 |
| Hattingen, E | 1 |
| Franz, K | 1 |
| Steinbach, J | 1 |
| Bähr, O | 1 |
| Pilatus, U | 1 |
| Ward, SM | 1 |
| Skinner, M | 1 |
| Saha, B | 1 |
| Emrick, T | 1 |
| Han, L | 1 |
| Liu, C | 1 |
| Qi, H | 1 |
| Zhou, J | 1 |
| Wen, J | 1 |
| Wu, D | 1 |
| Xu, D | 1 |
| Qin, M | 1 |
| Ren, J | 1 |
| Wang, Q | 1 |
| Liu, Y | 1 |
| Chen, I | 1 |
| Lu, Y | 1 |
| Kang, C | 1 |
| Gavrilovic, IT | 1 |
| Qin, LS | 1 |
| Yu, ZQ | 1 |
| Zhang, SM | 1 |
| Sun, G | 1 |
| Zhu, J | 1 |
| Xu, J | 1 |
| Guo, J | 1 |
| Fu, LS | 1 |
| Maudsley, AA | 1 |
| Gupta, RK | 1 |
| Stoyanova, R | 1 |
| Parra, NA | 1 |
| Roy, B | 1 |
| Sheriff, S | 1 |
| Hussain, N | 1 |
| Behari, S | 1 |
| Veenman, L | 2 |
| Gavish, M | 2 |
| Kugler, W | 7 |
| Swanson, KI | 2 |
| Clark, PA | 1 |
| Zhang, RR | 2 |
| Kandela, IK | 1 |
| Farhoud, M | 1 |
| Weichert, JP | 2 |
| Kuo, JS | 2 |
| Ríos-Marco, P | 1 |
| Ríos, A | 1 |
| Jiménez-López, JM | 1 |
| Carrasco, MP | 1 |
| Marco, C | 1 |
| Hall, LT | 1 |
| Alten, J | 1 |
| Linnemannstöns, K | 1 |
| Shandalov, Y | 1 |
| Zeno, S | 1 |
| Lakomek, M | 6 |
| Aki, A | 1 |
| Nair, BG | 1 |
| Morimoto, H | 1 |
| Kumar, DS | 1 |
| Maekawa, T | 1 |
| Oh, DY | 1 |
| Nakamura, K | 1 |
| Thiele, CJ | 1 |
| Belden, CJ | 1 |
| Valdes, PA | 1 |
| Ran, C | 1 |
| Pastel, DA | 1 |
| Harris, BT | 1 |
| Fadul, CE | 1 |
| Israel, MA | 1 |
| Paulsen, K | 1 |
| Roberts, DW | 1 |
| Thakur, A | 1 |
| Joshi, N | 1 |
| Shanmugam, T | 1 |
| Jendrossek, V | 5 |
| Hammersen, K | 1 |
| Erdlenbruch, B | 5 |
| Krügener, R | 1 |
| Eibl, H | 5 |
| Lehtimäki, KK | 1 |
| Valonen, PK | 1 |
| Griffin, JL | 1 |
| Väisänen, TH | 1 |
| Gröhn, OH | 1 |
| Kettunen, MI | 1 |
| Vepsäläinen, J | 1 |
| Ylä-Herttuala, S | 1 |
| Nicholson, J | 1 |
| Kauppinen, RA | 1 |
| Naumann, U | 1 |
| Wischhusen, J | 1 |
| Weit, S | 1 |
| Rieger, J | 1 |
| Wolburg, H | 1 |
| Massing, U | 1 |
| Weller, M | 1 |
| Otten, K | 1 |
| Albers, MJ | 1 |
| Krieger, MD | 1 |
| Gonzalez-Gomez, I | 1 |
| Gilles, FH | 1 |
| McComb, JG | 1 |
| Nelson, MD | 1 |
| Blüml, S | 1 |
| Chernov, MF | 1 |
| Hayashi, M | 1 |
| Izawa, M | 1 |
| Abe, K | 1 |
| Usukura, M | 1 |
| Ono, Y | 1 |
| Kubo, O | 1 |
| Hori, T | 1 |
| Loening, NM | 1 |
| Chamberlin, AM | 1 |
| Zepeda, AG | 1 |
| Gonzalez, RG | 2 |
| Cheng, LL | 2 |
| Momota, H | 1 |
| Nerio, E | 1 |
| de la Peña, L | 1 |
| Burgan, WE | 1 |
| Carter, DJ | 1 |
| Hollingshead, MG | 1 |
| Satyamitra, M | 1 |
| Camphausen, K | 1 |
| Tofilon, PJ | 1 |
| Chang, L | 2 |
| McBride, D | 2 |
| Miller, BL | 2 |
| Cornford, M | 2 |
| Booth, RA | 1 |
| Buchthal, SD | 1 |
| Ernst, TM | 1 |
| Jenden, D | 1 |
| Booth, R | 1 |
| Ernst, T | 1 |
| Nikas, D | 1 |
| Jenden, DJ | 1 |
| Hunold, A | 1 |
| Sabatier, J | 1 |
| Gilard, V | 1 |
| Malet-Martino, M | 1 |
| Ranjeva, JP | 1 |
| Terral, C | 1 |
| Breil, S | 1 |
| Delisle, MB | 1 |
| Manelfe, C | 1 |
| Tremoulet, M | 1 |
| Berry, I | 1 |
| Dygas, A | 1 |
| Sidorko, M | 1 |
| Bobeszko, M | 1 |
| Barańska, J | 2 |
| Wójcik, M | 1 |
| Anthony, DC | 1 |
| Comite, AR | 1 |
| Black, PM | 1 |
| Tzika, AA | 1 |
| Son, BC | 1 |
| Kim, MC | 1 |
| Choi, BG | 1 |
| Kim, EN | 1 |
| Baik, HM | 1 |
| Choe, BY | 1 |
| Naruse, S | 1 |
| Kang, JK | 1 |
| Zeller, WJ | 1 |
| Bauer, S | 1 |
| Remmele, T | 1 |
| Wowra, B | 1 |
| Sturm, V | 1 |
| Stricker, H | 1 |
| Hubesch, B | 1 |
| Sappey-Marinier, D | 1 |
| Roth, K | 1 |
| Meyerhoff, DJ | 1 |
| Matson, GB | 1 |
| Weiner, MW | 1 |
2 reviews available for phosphorylcholine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Apoptosis induction by erucylphosphohomocholine via the 18 kDa mitochondrial translocator protein: implications for cancer treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Membrane; Erucic Acids; Glioblastom | 2014 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell S | 2011 |
2 trials available for phosphorylcholine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma | 2020 |
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Ne | 2019 |
38 other studies available for phosphorylcholine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Smart Nanomedicine to Enable Crossing Blood-Brain Barrier Delivery of Checkpoint Blockade Antibody for Immunotherapy of Glioma.
Topics: Animals; Antibodies; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Glioma; Immunotherapy; | 2022 |
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
PMPC Modified PAMAM Dendrimer Enhances Brain Tumor-Targeted Drug Delivery.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Dendrimers; Doxorubicin; Drug Carri | 2021 |
Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Blood-Brain Barrier; Brain Neoplas | 2017 |
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor | 2017 |
In vivo Metabolic Profiles as Determined by
Topics: Adult; Aged; Analysis of Variance; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Diagnosis, Diffe | 2019 |
Polymer-Temozolomide Conjugates as Therapeutics for Treating Glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Compoundin | 2018 |
Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy.
Topics: Acetylcholine; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Blood-Brain Barrier; Brain; B | 2019 |
The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Membrane Permeability; Cell Proliferation; Cell Survival | 2013 |
Mapping of glycine distributions in gliomas.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain; Brain Mapping; Brain Neoplasms; Choline; Diffusion Magn | 2014 |
Fluorescent cancer-selective alkylphosphocholine analogs for intraoperative glioma detection.
Topics: Aminolevulinic Acid; Animals; Brain Neoplasms; Flow Cytometry; Fluorescent Dyes; Glioma; Heterograft | 2015 |
Cholesterol homeostasis and autophagic flux in perifosine-treated human hepatoblastoma HepG2 and glioblastoma U-87 MG cell lines.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Cholesterol; Glioblastoma; Hepatoblastoma; Homeostasis | 2015 |
Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.
Topics: Antineoplastic Agents; Brain Neoplasms; Disease Management; Glioblastoma; Humans; Multimodal Imaging | 2016 |
Potential involvement of F0F1-ATP(synth)ase and reactive oxygen species in apoptosis induction by the antineoplastic agent erucylphosphohomocholine in glioblastoma cell lines : a mechanism for induction of apoptosis via the 18 kDa mitochondrial translocat
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Butylated Hydroxyanisole; | 2010 |
Label-free determination of the number of biomolecules attached to cells by measurement of the cell's electrophoretic mobility in a microchannel.
Topics: Antibodies; Brain Neoplasms; Cell Biology; Cell Line, Tumor; Dimethylpolysiloxanes; Electrophoresis; | 2010 |
Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Drug Resistance, Neoplasm; Eto | 2011 |
Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cell | 2013 |
Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Division; Cell Survival | 2002 |
Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Glioma; Glycerol; Injec | 2002 |
Metabolite changes in BT4C rat gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death as studied by 1H NMR spectroscopy in vivo, ex vivo, and in vitro.
Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Choline; Diffusion; Ganciclovir; Genet | 2003 |
Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation.
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; bcl-X Protein; Brain Neoplasms; Caspases; Cell Line, T | 2004 |
MAP kinase pathways involved in glioblastoma response to erucylphosphocholine.
Topics: Brain Neoplasms; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Glioblastoma; Human | 2004 |
Proton-decoupled 31P MRS in untreated pediatric brain tumors.
Topics: Brain; Brain Neoplasms; Case-Control Studies; Child; Choline; Creatine; Ethanolamines; Female; Glyce | 2005 |
Early metabolic changes in metastatic brain tumors after Gamma Knife radiosurgery: 1H-MRS study.
Topics: Aged; Aspartic Acid; Brain Neoplasms; Creatine; Female; Glycerylphosphorylcholine; Humans; Lactic Ac | 2004 |
Quantification of phosphocholine and glycerophosphocholine with 31P edited 1H NMR spectroscopy.
Topics: Biomarkers, Tumor; Brain Chemistry; Brain Neoplasms; Glycerylphosphorylcholine; Humans; Molecular St | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell G | 2005 |
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Immunohistoc | 2006 |
Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors.
Topics: Adult; Brain Neoplasms; Choline; Creatine; Female; Glycerylphosphorylcholine; Humans; Hydrogen; Lact | 1995 |
In vivo 1H MRS choline: correlation with in vitro chemistry/histology.
Topics: Brain; Brain Neoplasms; Choline; Gas Chromatography-Mass Spectrometry; Glycerylphosphorylcholine; Hu | 1996 |
Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blood-Brain Barrier; Brain; Brain Neoplasms; DNA Fragment | 1999 |
Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Choline; Female; Glioma; Humans; In Vitro Techniques; Magnetic Resonan | 1999 |
Exogenous sphingosine 1-phosphate and sphingosylphosphorylcholine do not stimulate phospholipase D in C6 glioma cells.
Topics: Brain Neoplasms; Enzyme Activation; Glioma; Lysophospholipids; Phospholipase D; Phosphorylcholine; S | 1999 |
Sphingosine, sphingosylphosphorylcholine and sphingosine 1-phosphate modulate phosphatidylserine homeostasis in glioma C6 cells.
Topics: Brain Neoplasms; Glioma; Homeostasis; Lysophospholipids; Phosphorylcholine; Sphingosine; Tumor Cells | 1999 |
Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy.
Topics: Adult; Biopsy; Brain Neoplasms; Choline; Glioblastoma; Gliosis; Humans; Lactates; Lipids; Magnetic R | 2000 |
Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy.
Topics: Adult; Aspartic Acid; Biopsy, Needle; Brain; Brain Neoplasms; Creatine; Diagnosis, Differential; Ene | 2001 |
Induction of differentiation and tetraploidy by long-term treatment of C6 rat glioma cells with erucylphosphocholine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Differentiation; Cell D | 2001 |
Interstitial chemotherapy of experimental gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Gl | 1990 |
P-31 MR spectroscopy of normal human brain and brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain; Brain Neoplasms; Female; Humans; Image Processing, Comp | 1990 |